97163 ⎘
Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons; Interleukins [IL] IL-6
Treatment of diuretic resistant heart failure patients having at least one copy of the TMPRSS6 rs855791 allele
#2PRE-MEDICATION AND IMPROVED TREATMENT REGIMEN
#3METHODS AND COMPOSITIONS FOR CANCER TREATMENT
#4SUBCUTANEOUS ADMINISTRATION OF ANTIBODIES FOR THE TREATMENT OF DISEASE
#5METHODS AND COMPOSITIONS INVOLVING CHIMERIC BINDING POLYPEPTIDES
#6METHODS FOR THE TREATMENT OF THYROID EYE DISEASE
#7METHOD OF CONCENTRATING A SOLUTION OR FORMULATION
#8Targeting the Interplay of Treg Cells and Hepatic Stellate Cells in Liver Fibrosis and Insulin Resistance
#9METHODS FOR TREATING PULMONARY FIBROTIC DISEASES OR DISORDERS WITH AN ANTI-ONCOSTATIN M RECEPTOR BETA ANTIBODY
#10METHODS OF TREATING THE EFFECTS OF CYTOKINE STORMS
#11ENGINEERED IMMUNOSTIMULATORY BACTERIAL STRAINS AND USES THEREOF
#12ANTI IL-6 DOMAIN ANTIBODIES WITH FATTY ACID SUBSTITUENTS
#13PREDICTING RESPONSE TO IL-6 ANTAGONISTS
#14Clazakizumab in the Treatment of Chronic Antibody-Mediated Rejection of Organ Transplant
#15ONCOSTATIN M RECEPTOR ANTIGEN BINDING PROTEINS
#16Compounds
#17COMBINATIONS OF IL15/IL15R ALPHA HETERODIMERIC FC-FUSION PROTEINS AND FCRH5XCD3 BISPECIFIC ANTIBODIES FOR THE TREATMENT OF BLOOD CANCERS
#18STABILIZED FORMULATIONS CONTAINING ANTI-INTERLEUKIN-6 RECEPTOR (IL-6R) ANTIBODIES
#19IL-6 INHIBITOR AS TREATMENT FOR NEPHROPATHY
#20ANTIBODY THAT BINDS TO VEGF-A AND IL6 AND METHODS OF USE
#21METHODS FOR TREATING HEPCIDIN-MEDIATED DISORDERS
#22ANTI IL-6 DOMAIN ANTIBODIES
#23COMBINATION THERAPIES INCLUDING PARP1 INHIBITORS
#24METHODS FOR THE TREATMENT OF MYASTHENIA GRAVIS
#25IL-6 ANTIBODIES
#26REEXPRESSION OF HNF4A TO ALLEVIATE CANCER-ASSOCIATED CACHEXIA
#27METHODS AND COMPOSITIONS FOR SUPPRESSING AGING-ASSOCIATED CLONAL HEMATOPOIESIS
#28METHODS FOR THE TREATMENT OF THYROID EYE DISEASE
#29METHODS FOR THE TREATMENT OF CARDIOVASCULAR DISEASE
#30COMPOSITION FOR TREATING SOLID MALIGNANT TUMOR, AND KIT FOR TREATING SOLID MALIGNANT TUMOR
#31PROTEIN SIGNATURES FOR DISTINGUISHING BETWEEN BACTERIAL AND VIRAL INFECTIONS
#32Treatment of pneumonia and ARDS with inhibitors of C5a and IL-6 activity
#33METHOD OF TREATING CANCER WITH A CANCER THERAPY IN COMBINATION WITH ANOTHER THERAPEUTIC AGENT
#34IL-6 ANTIBODIES AND FUSION CONSTRUCTS AND CONJUGATES THEREOF
#35COMPOSITIONS AND METHODS FOR TREATMENT OF THYROID EYE DISEASE
#36ANTIBODIES COMPRISING A POLYPEPTIDE INSERTED IN FRAMEWORK 3 REGION
#37METHODS FOR THE TREATMENT OF CANCER
#38POLYPEPTIDES COMPRISING IMMUNOGLOBULIN SINGLE VARIABLE DOMAINS TARGETING IL-6 AND TNF ALPHA
#39ANTIGEN-BINDING MOLECULE PROMOTING DISAPPEARANCE OF ANTIGENS HAVING PLURALITY OF BIOLOGICAL ACTIVITIES
#40METHOD FOR PROPHYLACTIC THERAPY OF CYTOKINE RELEASE SYNDROME AND/OR IMMUNE EFFECTOR CELL-ASSOCIATED NEUROTOXICITY SYNDROME (ICANS)
#41BI-SPECIFIC CHIMERIC ANTIGEN RECEPTORS AND GENETICALLY ENGINEERED IMMUNE CELLS EXPRESSING SUCH
#42METHODS FOR TREATING HIGH RISK MYELODYSPLASTIC SYNDROMES
#43USE OF IL-6 ANTIBODIES AND VEGF TRAPS, AND FUSION CONSTRUCTS AND CONJUGATES THEREOF
#44ANTIGEN-BINDING MOLECULES, THE ANTIGEN-BINDING ACTIVITY OF WHICH VARIES ACCORDING TO THE CONCENTRATION OF COMPOUNDS, AND LIBRARIES OF SAID MOLECULES
#45IL-6 BINDING MOLECULES
#46ANTIGEN-BINDING MOLECULE CAPABLE OF BINDING TO PLURALITY OF ANTIGEN MOLECULES REPEATEDLY
#47MODIFICATION OF IMMUNE CELLS FOR REDUCING TOXICITY AND USES THEREOF IN ADOPTIVE CELL THERAPY
#48METHODS FOR TREATING HIGH RISK MYELODYSPLASTIC SYNDROMES
#49Use of Anti-Il-6 Antibody, e.g., Clazakizumab for Desensitization of Solid Organ Transplant Recipients and/or for Preventing, Stabilizing or Reducing Antibody Mediated Rejection (ABMR)
#50LDL RECEPTOR-DIRECTED BISPECIFIC BINDING AGENT-LIGAND FUSIONS FOR THE DEGRADATION OF TARGET PROTEINS
#51VHH POLYPEPTIDES THAT BIND TO INTERLEUKIN 6 (IL-6), COMPOSITIONS AND METHODS OF USE THEREOF
#52PREVENTION AND TREATMENT OF STEROID-RESISTANT OR GUT GRAFT-VERSUS-HOST DISEASE (GVHD)
#53METHODS OF ADMINISTERING CHIMERIC ANTIGEN RECEPTOR IMMUNOTHERAPY
#54METHOD FOR PREDICTING AND EVALUATING THERAPEUTIC EFFECT IN DISEASES RELATED TO IL-6 AND NEUTROPHILS
#55METHOD FOR TREATING PNEUMONIA, INCLUDING COVID-19 PNEUMONIA, WITH AN IL6 ANTAGONIST
#56ANTIGEN-BINDING MOLECULE CAPABLE OF BINDING TO TWO OR MORE ANTIGEN MOLECULES REPEATEDLY
#57USE OF IL-6 INHIBITORS FOR THE TREATMENT OF ACUTE CHEST SYNDROME IN PATIENTS SUFFERING FROM SICKLE CELL DISEASE
#58THERAPEUTIC AGENT FOR PERIPARTUM CARDIOMYOPATHY
#59METHODS FOR TREATING OR REDUCING THE SEVERITY OF A VIRAL INFECTION
#60PHARMACEUTICAL COMPOSITION FOR THE PREVENTION OR TREATMENT OF POST-SURGICAL PAIN
#61METHODS FOR TREATING CARDIOVASCULAR DISEASE
#62DUAL TARGETING
#63TARGET TISSUE-SPECIFIC ANTIGEN-BINDING MOLECULE
#64EXPANDED MEMORY SUBSETS OF GAMMA DELTA T CELLS FOR IMMUNOTHERAPY
#65IMPLANTABLE SCAFFOLDS AND USES THEREOF FOR IMMUNOTHERAPY AND OTHER USES
#66AXL Inhibitors for Antiviral Therapy
#67ANTIBODIES WITH MODIFIED AFFINITY TO FCRN THAT PROMOTE ANTIGEN CLEARANCE
#68Tissue-homing peptide conjugates and methods of use thereof
#69COMPOSITIONS AND METHODS FOR TREATMENT OF ACUTE RESPIRATORY DISTRESS SYNDROME
#70Use of Anti-IL-6 Antibody, e.g., Clazakizumab for Treatment/Prevention of ARDS Associated with Coronavirus (COVID-19) Infection
#71PREVENTION OF VISIBLE PARTICLE FORMATION IN PARENTERAL PROTEIN SOLUTIONS
#72TARGETED THERAPY FOR THE TREATMENT & PREVENTION OF LIFE-THREATENING COMPLICATIONS OF INFECTION
#73Dosing Strategy that Mitigates Cytokine Release Syndrome for Therapeutic Antibodies
#74COMPOSITIONS AND METHOD OF MODULATING GROWTH FACTOR FUNCTION
#75METHODS AND COMPOSITIONS TO ENHANCE HUMORAL IMMUNITY TO REDUCE CYTOMEGALOVIRUS INFECTION AND REACTIVATION BY IL-6 INHIBITION
#76GENETICALLY MODIFIED IMMUNE CELLS EXPRESSING A CHIMERIC ANTIGEN RECEPTOR AND HAVING REDUCED PROINFLAMMATORY CYTOKINE SIGNALING
#77METHOD FOR THE PRODUCTION AND PURIFICATION OF MULTIVALENT IMMUNOGLOBULIN SINGLE VARIABLE DOMAINS
#78METHODS TO PREVENT, AMELIORATE AND TREAT COMPLICATIONS FROM VIRAL INFECTIONS
#79MONOCLONAL ANTIBODY
#80USE OF ANTIBODY DRUG CONJUGATES COMPRISING TUBULIN DISRUPTING AGENTS TO TREAT SOLID TUMOR
#81A METHOD FOR TREATING DISEASE USING FOXP3+CD4+ T CELLS
#82METHODS FOR TREATING IL-6 MEDIATED INFLAMMATION WITHOUT IMMUNOSUPPRESSION
#83METHODS FOR TREATING AND EVALUATING COVID-19 PATIENTS
#84Engineered immunostimulatory bacterial strains and uses thereof
#85Formulations for Enteric Delivery of Therapeutic Agents
#86NK CELL-BASED THERAPY
#87BIOMARKERS AND USES THEREOF FOR SELECTING IMMUNOTHERAPY INTERVENTION
#88TREATMENT OF FIBROSIS WITH COMBINED BLOCKADE OF IL-6 AND IMMUNE CHECKPOINT
#89IMPLANTABLE SCAFFOLDS AND USES THEREOF FOR IMMUNOTHERAPY AND OTHER USES
#90ANTI-HUMAN IL6 MONOCLONAL ANTIBODIES, PREPARATION METHOD THEREFOR AND USE THEREOF
#91METHODS AND COMPOSITIONS INVOLVING CHIMERIC BINDING POLYPEPTIDES
#92Readily Isolated Bispecific Antibodies with Native Immunoglobulin Format
#93IMMUNOSTIMULATORY BACTERIA DELIVERY PLATFORMS AND THEIR USE FOR DELIVERY OF THERAPEUTIC PRODUCTS
#94Polypeptides comprising immunoglobulin chain variable domains which bind to interleukin-6 receptor (IL-6R) and methods of use thereof to treat autoimmune and inflammatory diseases
#95CHIMERIC ANTIGEN RECEPTOR T CELL THERAPY
#96Polypeptides comprising immunoglobulin single variable domains targeting IL-6 and TNF-α
#97METHODS FOR THE TREATMENT OF THYROID EYE DISEASE
#98SUBCUTANEOUS ADMINISTRATION OF ANTIBODIES FOR THE TREATMENT OF DISEASE
#99EXPRESS HUMANIZATION OF ANTIBODIES
#100Engineered immunostimulatory bacterial strains and uses thereof
#101Clonal Hematopoiesis and Risk of Chronic Liver Disease
#102METHODS AND COMPOSITIONS FOR THE IMPROVEMENT OF LYSOSOMAL FUNCTION AND TREATMENT OF NEURODEGENERATIVE DISEASE
#103COMPOSITIONS AND METHODS FOR TREATING LUNG, COLORECTAL AND BREAST CANCER
#104IL-6 antagonist formulations and uses thereof
#105METHODS FOR TREATING IL-6 MEDIATED INFLAMMATION WITHOUT IMMUNOSUPPRESSION
#106THERAPEUTIC AGENT FOR UROLOGICAL CANCER WHICH IS CHARACTERIZED BY BEING ADMINISTERED WITH IL-6 INHIBITOR AND CCR2 INHIBITOR IN COMBINATION
#107Treatment of existing left ventricular heart failure
#108Anti-interleukin-6 receptor antibodies
#109METHOD FOR INHIBITING PLATELET DERIVED GROWTH FACTOR SIGNALING WITH C3aR OR C5aR ANTIBODIES
#110IL-6 ANTIBODIES
#111METHOD FOR TREATING DISEASE USING FOXP3+CD4+ T CELLS
#112IMMUNOSTIMULATORY BACTERIA DELIVERY PLATFORMS AND THEIR USE FOR DELIVERY OF THERAPEUTIC PRODUCTS
#113ANTIGEN-BINDING MOLECULE CONTAINING ANTIGEN-BINDING DOMAIN OF WHICH BINDING ACTIVITY TO ANTIGEN IS CHANGED DEPENDING ON MTA, AND LIBRARY FOR OBTAINING SAID ANTIGEN-BINDING DOMAIN
#114IDENTIFICATION AND TARGETING OF TUMOR PROMOTING CARCINOMA ASSOCIATED FIBROBLASTS FOR DIAGNOSIS AND TREATMENT OF CANCER AND OTHER DISEASES
#115Method for treating disease using FOXP3+CD4+ T cells
#116PEPTIDE IMMUNOGENS TARGETING INTERLEUKIN 6 (IL-6) AND FORMULATIONS THEREOF FOR IMMUNOTHERAPY OF DISEASES IMPACTED BY IL-6 DYSREGULATION
#117MODIFIED IMMUNE CELLS CO-EXPRESSING CHIMERIC ANTIGEN RECEPTOR AND IL-6 ANTAGONIST FOR REDUCING TOXICITY AND USES THEREOF IN ADOPTIVE CELL THERAPY
#118CLAZAKIZUMAB IN THE TREATMENT OF CHRONIC ANTIBODY-MEDIATED REJECTION OF ORGAN TRANSPLANT
#119IL-6 binding molecules
#120Antibodies comprising a polypeptide inserted in framework 3 region
#121Oncostatin M receptor antigen binding proteins
#122Anti-IL-6 antibody
#123Anti-IL-6 Antibody Formulation
#124METHODS AND COMPOSITIONS FOR TREATING ASTHMA
#125Readily isolated bispecific antibodies with native immunoglobulin format
#126Anti-IL6 Agent for Treating Coronavirus Infection
#127Protein signatures for distinguishing between bacterial and viral infections
#128Methods and Compositions Relating to p62/SQSTM1 for the Treatment and Prevention of Inflammation-Associated Diseases
#129Formulation of tocilizumab and method for treating COVID-19 by inhalation
#130USE OF CLAZAKIZUMAB TO DESENSITIZE AND IMPROVE RENAL TRANSPLANTATION IN HLA-SENSITIZED PATIENTS
#131HUMANIZED MONOCLONAL ANTIBODIES AGAINST INTERLEUKIN-6, ENCODING GENES AND USES THEREOF
#132Compounds
#133THERAPEUTIC AGENT FOR ASTHMA CONTAINING IL-6 INHIBITOR
#134INHIBITION OF KIDNEY DISEASE RELAPSE BY TARGETED CYTOKINE DEPLETION
#135ANTI-IL-6 ANTIBODIES FOR THE TREATMENT OF ORAL MUCOSITIS
#136USING C1 ESTERASE INHIBITOR TO TREAT VIRAL INFECTION-RELATED ACUTE RESPIRATORY DISTRESS
#137Proteins and Uses
#138CONTROLLED RELEASE OF ANTIBODIES TO MODULATE CYTOKINES
#139METHODS FOR TREATING HEPCIDIN-MEDIATED DISORDERS
#140CARTILAGE-HOMING PEPTIDE CONJUGATES AND METHODS OF USE THEREOF
#141Treatment or prevention of diseases and disorders associated with cells that express IL-6 with Anti-IL-6 antibodies
#142Stabilized formulations containing anti-interleukin-6 receptor (IL-6R) antibodies
#143Interleukin-2 and use thereof
#144Antigen-binding molecules, the antigen-binding activity of which varies according to the concentration of compounds, and libraries of said molecules
#145DOSAGE REGIMEN
#146Methods and compounds for improved immune cell therapy
#147POLYPEPTIDE IMPROVED IN PROTEIN PURITY AND AFFINITY FOR ANTIGEN, CONJUGATE THEREOF WITH ANTIBODY OR ANTIGEN-BINDING FRAGMENT, AND PREPARATION METHOD THEREFOR
#148ANTAGONISTS OF IL-6 TO PREVENT OR TREAT CACHEXIA, WEAKNESS, FATIGUE, AND/OR FEVER
#149Coated egg yolk cores, methods of making and methods of use thereof
#150Antigen-binding molecule capable of binding to two or more antigen molecules repeatedly
#151Antigen-binding molecule capable of binding two or more antigen molecules repeatedly
#152DUAL TARGETING
#153Use of Anti-Il-6 Antibody, e.g., Clazakizumab for Desensitization of Solid Organ Transplant Recipients and/or for Preventing, Stabilizing or Reducing Antibody Mediated Rejection (ABMR)
#154ENGINEERED IMMUNOSTIMULATORY BACTERIAL STRAINS AND USES THEREOF
#155Neutralization of Human Cytokines with Membrane-Bound Anti-Cytokine Non-Signaling Binders Expressed in Immune Cells
#156ANTIGEN BINDING PROTEINS TO ONCOSTATIN M (OSM)
#157Modification of immune cells for reducing toxicity and uses thereof in adoptive cell therapy
#158METHOD OF TREATMENT WITH VIRAL-BASED GENE THERAPY
#159Delivering biological drugs to tissues
#160Anti-IL-6/IL-6R antibodies and methods of use thereof
#161ANTAGONISTS OF IL-6 TO PREVENT OR TREAT CACHEXIA, WEAKNESS, FATIGUE, AND /OR FEVER
#162METHODS AND COMPOSITIONS FOR THE IMPROVEMENT OF LYSOSOMAL FUNCTION AND TREATMENT OF NEURODEGENERATIVE DISEASE
#163HARNESSING PROTEIN-BASED DRUGS COMPRISING AN ANCHOR DOMAIN FOR USE ON THE OCULAR SURFACE
#164ANTIBODY PRODUCING NON-HUMAN ANIMALS
#165Composition to induce bone marrow stem cell mobilization
#166Polypeptides which bind to interleukin-6 receptor (IL-6R)
#167Chemotherapeutic methods for treating low-proliferative disseminated tumor cells
#168Engineered immunostimulatory bacterial strains and uses thereof
#169Compositions and methods for treating alzheimer's disease
#170Method of treating cancer with a cancer therapy in combination with another therapeutic agent
#171METHODS OF PURIFYING BISPECIFIC ANTIBODIES
#172Method for purifying anti-IL-6 receptor antibodies
#173Express humanization of antibodies
#174Method for predicting and evaluating therapeutic effect in diseases related to IL-6 and neutrophils
#175ANTI-IL-6 ANTIBODIES FOR THE TREATMENT OF ANEMIA
#176Dosing strategy that mitigates cytokine release syndrome for therapeutic antibodies
#177Methods of suppressing rheumatoid arthritis using an anti-IL-6 antibody
#178ANTIBODIES TO IL-6 AND USE THEREOF
#179COMBINATION THERAPY OF ANTIBODIES ACTIVATING HUMAN CD40 AND ANTIBODIES AGAINST HUMAN PD-L1
#180ANTAGONISTS OF IL-6 TO RAISE ALBUMIN AND/OR LOWER CRP
#181ANTIBODIES TO IL-6 AND USE THEREOF
#182Treatment of existing left ventricular heart failure
#183Compounds
#184Cartilage-homing peptide conjugates and methods of use thereof
#185COMBINATION THERAPIES AND METHODS USING ANTI-CD3 MODULATING AGENTS AND ANTI-IL-6 ANTAGONISTS
#186ANTIGEN-BINDING MOLECULE CAPABLE OF BINDING TO TWO OR MORE ANTIGEN MOLECULES REPEATEDLY
#187ANTIBODIES TO IL-6 AND USE THEREOF
#188ANTAGONISTS OF IL-6 TO RAISE ALBUMIN AND/OR LOWER CRP
#189Biomarkers and uses thereof for selecting immunotherapy intervention
#190ONCOSTATIN M RECEPTOR ANTIGEN BINDING PROTEINS
#191Target tissue-specific antigen-binding molecule
#192Anti-Interleukin-6 receptor antibodies
#193Use of Antibody Drug Conjugates Comprising Tubulin Disrupting Agents to Treat Solid Tumor
#194Methods for the treatment of thyroid eye disease
#195IL-6 antibodies and fusion constructs and conjugates thereof
#196ANTAGONISTS OF IL-6 TO PREVENT OR TREAT CACHEXIA, WEAKNESS, FATIGUE, AND/OR FEVER
#197Methods for treating IL-6 mediated inflammation without immunosuppression
#198METHODS FOR TREATING IL-6 MEDIATED INFLAMMATION WITHOUT IMMUNOSUPPRESSION
#199IL-6 binding molecules
#200Platforms and methods for optimizing host antigen presentation and host antitumor and antipathogen immunity
#201Drug containing carrier into cell for forming immune complex
#202Antibody or an antigen-binding fragment thereof capable of binding to a human receptor of interleukin-6
#203IL-6 antibodies
#204DNA Monoclonal Antibodies Targeting IL-6 and CD126
#205Methods for producing antibodies promoting disappearance of antigens having plurality of biological activities
#206Antagonists of IL-6 to prevent or treat thrombosis
#207Methods and compositions relating to p62/SQSTM1 for the treatment and prevention of inflammation-associated diseases
#208METHODS OF ADMINISTERING CHIMERIC ANTIGEN RECEPTOR IMMUNOTHERAPY
#209Method of Predicting Personalized Response to Cancer Therapy, Method of Treating Cancer, and Kit Therefor
#210DNA monoclonal antibodies targeting influenza virus
#211Therapeutic compositions and methods with cytokine signaling immunomodulators
#212Protein signatures for distinguishing between bacterial and viral infections
#213Antibody recognizing human leukemia inhibitory factor (LIF) and use of anti-LIF antibodies in the treatment of diseases associated with unwanted cell proliferation
#214yeast cultures comprising reduced antibody-associated variants
#215Method of predicting personalized response to cancer treatment with immune checkpoint inhibitors, method of treating cancer, and kit therefor
#216COMPOSITIONS AND METHODS FOR TREATING RHEUMATOID ARTHRITIS
#217Method of treating osteoarthritis with human oncostatin M antibodies
#218Polypeptides
#219Antagonists to IL-6 to Raise Albumin and/or Lower CRP
#220Antagonists of IL-6 to prevent or treat cachexia, weakness, fatigue, and /or fever
#221ANTIBODIES TO IL-6 AND USE THEREOF
#222IL-6 ANTAGONIST FORMULATIONS AND USES THEREOF
#223Coated egg yolk cores, methods of making and methods of use thereof
#224METHODS OF PURIFYING ANTIBODIES
#225Readily isolated bispecific antibodies with native immunoglobulin format
#226ANTI-IL-6 ANTIBODIES FOR THE TREATMENT OF ORAL MUCOSITIS
#227Antagonists of IL-6 to raise albumin and/or lower CRP
#228Antagonists of IL-6 to prevent or treat thrombosis
#229Stabilized formulations containing anti-interleukin-6 receptor (IL-6R) antibodies
#230Antibodies to IL-6 and use thereof
#231MEANS AND METHODS FOR PREPARING ENGINEERED PROTEINS BY GENETIC CODE EXPANSION IN INSECT CELLS
#232Compositions and methods for modulating an immune response
#233Ligand-guided phagocytosis based therapy for treatment of Alzheimer's disease and other neurodegenerative diseases
#234Compositions and methods for ameliorating CNS inflammation, psychosis, delirium, PTSD or PTSS
#235ANTIGEN-BINDING MOLECULE CAPABLE OF BINDING TWO OR MORE ANTIGEN MOLECULES REPEATEDLY
#236Antigen-binding molecule capable of binding two or more antigen molecules repeatedly
#237Antigen-binding molecule capable of binding to plurality of antigen molecules repeatedly
#238Antibodies against LIF and uses thereof
#239THERAPEUTIC AGENT FOR CHRONIC ARTHRITIDES DISEASES OF CHILDHOOD-RELATED DISEASES
#240IL-6 antagonists and uses thereof
#241Antibodies to IL-6 and use thereof
#242In vivo Imaging using Anti-IL-6 Antibodies
#243Murine, chimeric, humanized or human anti-TNF-alpha antibodies
#244Antibodies to IL-6 and use thereof
#245Chimeric and humanized anti-histone antibodies
#246Antibodies against LIF and uses thereof
#247Compounds
#248ANTIBODY PRODUCING NON-HUMAN ANIMALS
#249ANTIBODY PRODUCING NON-HUMAN ANIMALS
#250Antibody producing non-human animals
#251ANTIBODY PRODUCING NON-HUMAN ANIMALS
#252Antibody producing non-human animals
#253Antibody producing non-human animals
#254Methods for the generation of multispecific and multivalent antibodies
#255ANTAGONISTS OF IL-6 TO PREVENT OR TREAT CACHEXIA, WEAKNESS, FATIGUE, AND/OR FEVER
#256Methods of treating autoimmunity using specific anti-IL-6 antibodies
#257Formulations for enteric delivery of therapeutic agents
#258DUAL TARGETING
#259Method of treating allergic asthma with antibodies to IL-6
#260Anti-IL-6/IL-6R antibodies and methods of use thereof
#261CONJUGATE AND USE THEREOF
#262COMBINATION THERAPY OF ANTIBODIES ACTIVATING HUMAN CD40 AND ANTIBODIES AGAINST HUMAN PD-L1
#263Antagonists of IL-6 to raise albumin and/or lower CRP
#264Antibody producing non-human animals
#265Isolated host cells expressing anti-IL-6 antibodies
#266Method for treating chronic intestinal inflammation and inflammatory bowel disease by administering antagonists of Oncostatin-M (OSM) and/or antagonists of OSM receptor-beta (OSMR)
#267Methods for treating ischemic stroke using chimeric and humanized anti-histone antibodies
#268Methods for the treatment of interleukin-6 receptor-related diseases and disorders
#269Oncostatin M receptor antigen binding proteins
#270Method for selecting a single cell expressing a heterogeneous combination of antibodies
#271Method of treating autoimmune disease by administering antibodies to interleukin-6
#272Antagonists of IL-6 to raise albumin and/or lower CRP
#273Anti-IL-6 vaccine composition
#274Composition to induce bone marrow stem cell mobilization
#275Cell lines
#276Amino acid derivatives
#277Treatment Methods for Rheumatoid Arthritis
#278Method for treating multiloculated hydrocephalus by administering an anti-IL6 receptor antibody
#279Treatment of Depression Using Agents that Block Binding of IL-6 to IL-6 Receptor
#280Murine, chimeric, humanized or human anti-IL-6 antibodies
#281Methods of modifying antibodies for purification of bispecific antibodies
#282Production of proteins in labyrinthulomycetes
#283REMOVAL OF MONOMERIC TARGETS
#284Methods of Suppressing Rheumatoid Arthritis Using An Anti-IL-6 Antibody
#285Express humanization of antibodies
#286COMPOSITIONS AND METHODS FOR TREATING B CELL MEDIATED AUTOIMMUNE DISORDERS
#287Methods for treating thrombosis using chimeric and humanized anti-histone antibodies
#288Antagonists of IL-6 to prevent or treat cachexia, weakness, fatigue, and/or fever
#289Oncostatin M (OSM) antagonists for preventing cancer metastasis and IL-6 related disorders
#290Carrier immunoglobulins
#291ANTIBODY MOLECULES HAVING SPECIFICITY FOR HUMAN IL-6
#292METHOD FOR TREATING ANTIBODY-MEDIATED REJECTION POST-TRANSPLANTATION
#293Antigen binding proteins to oncostatin M (OSM)
#294Method of treating idiopathic pulmonary fibrosis by administering human oncostatin M antibodies
#295IL-6-binding polypeptide complex
#296Methods of aiding in the diagnosis of diseases using anti-IL-6 antibodies
#297HUMAN ANTI IL-6 ANTIBODIES WITH EXTENDED IN VIVO HALF-LIFE AND THEIR USE IN TREATMENT OF ONCOLOGY, AUTOIMMUNE DISEASES AND INFLAMMATORY DISEASES
#298Methods related to biologics
#299Method for treating muscular dystrophy
#300METHODS FOR TREATING HEPCIDIN-MEDIATED DISORDERS